IJPR  articles are Indexed in SCOPUS (2010 - 2021)Click Here     *Five Years Citation in Google scholar (2016 - 2020) is. 1451*        Now IJPR is Q2 in SJR Ranking     Scopus Coverage of IJPR (2010-2021 Issue 1)            

logo

INTERNATIONAL JOURNAL OF PHARMACEUTICAL RESEARCH

A Step Towards Excellence

IJPR included in UGC-Approved List of Journals - Ref. No. is SL. No. 4812 & J. No. 63703

Published by : Advanced Scientific Research
ISSN
0975-2366
Current Issue
Article In Press
No Data found.
ADOBE READER

(Require Adobe Acrobat Reader to open, If you don't have Adobe Acrobat Reader)

Index Page 1
Click here to Download
IJPR 9[3] July - September 2017 Special Issue

July - September 9[3] 2017

Click to download
 

Article Detail

Label
Label
Effect of Add on Antidiabetic Drugs on Cognitive Scores in Type 2 Diabetes Mellitus Patients with Mild Cognitive Impairment

Author: SREEJITH K, MALARKODI VELRAJ
Abstract: Background & objectives: Type 2 diabetes mellitus increase the risk of developing cognitive decline. Antidiabetic drugs play multiple roles in prevention as well as aggravation of cognitive decline. This study aimed to assess the add on effect of commonly using anti-diabetic medicines on cognitive status among diabetic patients with mild cognitive impairment (MCI). Methods: A cross sectional study was conducted in a tertiary care teaching hospital. Montreal Cognitive Assessment (MoCA) and Addenbrooke’s Cognitive Examination III (ACE-III) were used to access the cognitive status on patients. Statistical analysis was performed by using SPSS version 21.0. Independent sample KruskalWallis test was used to analyze the outcome. Results: A total of 465 diabetes patients on treatment with metformin and/ or insulin and/ or glimipride were included in this study. The prevalence of MCI was found to 24.64%. The mean MoCA score for the patients with MCI was found to be 20.06 (SD: 1.10) and ACE-III score is 77.71 (SD: 1.89). MoCA scores were significantly different for add on antidiabetes drugs studied, H(2) =8.241, p=0.016. Significant difference was found when metformin as add on drug compared to Insulin as add on drug (p=0,024, r=-0.149). However no significant differences was found between MOCA score when metformin as add on drug compared to no second drug (p=0.225, r=0.089) and Insulin compared to no second drug (p=0.681, r= -0.083). Conclusion: Metformin helps significantly to improve cognitive impairment in type 2 diabetes mellitus patients as add on drug than insulin as add on drug.
Keyword: ACE-III, Cognitive impairment, Glimipride, Insulin, Metformin, MoCA
DOI: https://doi.org/10.31838/ijpr/2021.13.02.097
Download: Request For Article
 




ONLINE SUBMISSION
USER LOGIN


Username
Password
Login | Register
News & Events
SCImago Journal & Country Rank

Terms and Conditions
Disclaimer
Refund Policy
Instrucations for Subscribers
Privacy Policy

Copyrights Form

0.12
2018CiteScore
 
8th percentile
Powered by  Scopus
Google Scholar

hit counters free